Study identifier:NIS-CES-DUM-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Dyslipaemia, atherosclerosis risk and increased hsCRP and inflammatory and oxidative status in the Spanish population
Dyslipaemia
-
No
-
All
30181
Observational
35 Years - 74 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The present project is aimed at determining the prevalence of LDL-C <130 mg/dl with hsCRP ≥2mg/l, and of HDL-C < 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.
Location
Location
Girona, CATALUNA, Spain
Location
Canarias, Canarias, Spain
Location
Hospitalet, CATALUNA, Spain
Location
Talavero, Castilla la Mancha, Spain
Location
Badajoz, EXTREMADURA, Spain
Location
Castilla y Leon, CASTILLA LEON, Spain
Location
Navarra, NAVARRA, Spain
Location
Mallorca, Mallorca, Spain
Arms | Assigned Interventions |
---|---|
1 Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.